Abstract
The contemporary treatment of angina is centred around improving coronary arterial flow and increasing perfusion of ischaemic myocardium. This is variably achieved with medication, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The coronary sinus reducer (CSR; Neovasc Inc., Richmond, BC, Canada) is the only therapy which attempts to improve angina by acting on the postcapillary myocardial circulation. Unlike PCI, which has an intuitive, well-described, extensively investigated mechanism, how the CSR affects angina is not well understood. The CSR is an hourglass-shaped, balloon-mounted, wire-mesh device that reduces the coronary sinus lumen, after inflammation and fibrosis have caused ...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call